Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

Stock Information for Calithera Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calithera Biosciences Inc.

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.